The impact of G‐protein‐coupled receptor hetero‐oligomerization on function and pharmacology

Although highly controversial just a few years ago, the idea that G‐protein‐coupled receptors (GPCRs) may undergo homo‐oligomerization or hetero‐oligomerization has recently gained considerable attention. The recognition that GPCRs may exhibit either dimeric or oligomeric structures is based on a number of different biochemical and biophysical approaches. Although much effort has been spent to demonstrate the mechanism(s) by which GPCRs interact with each other, the physiological relevance of this phenomenon remains elusive. An additional source of uncertainty stems from the realization that homo‐oligomerization and hetero‐oligomerization of GPCRs may affect receptor binding and activity in different ways, depending on the type of interacting receptors. In this brief review, the functional and pharmacological effects of the hetero‐oligomerization of GPCR on binding and cell signaling are critically analyzed.

[1]  Horst Vogel,et al.  Oligomerization of the α1a- and α1b-Adrenergic Receptor Subtypes , 2003, Journal of Biological Chemistry.

[2]  M. Millan,et al.  Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole , 2003, Journal of neurochemistry.

[3]  P. Sigler,et al.  The 2.8 A crystal structure of visual arrestin: a model for arrestin's regulation. , 1999, Cell.

[4]  M. Scarselli,et al.  The Paired Activation of the Two Components of the Muscarinic M3 Receptor Dimer Is Required for Induction of ERK1/2 Phosphorylation* , 2004, Journal of Biological Chemistry.

[5]  P. Sokoloff,et al.  D2/D3 Dopamine Receptor Heterodimers Exhibit Unique Functional Properties* , 2001, The Journal of Biological Chemistry.

[6]  H. Vogel,et al.  Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. , 2003, The Journal of biological chemistry.

[7]  R. Lefkowitz Historical review: a brief history and personal retrospective of seven-transmembrane receptors. , 2004, Trends in pharmacological sciences.

[8]  Mario Mellado,et al.  Chemokine receptor homo‐ or heterodimerization activates distinct signaling pathways , 2001, The EMBO journal.

[9]  M. Bouvier,et al.  Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. , 2004, The Journal of biological chemistry.

[10]  Graeme Milligan,et al.  Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. , 2002, The Biochemical journal.

[11]  G. Büldt,et al.  X-ray crystal structure of arrestin from bovine rod outer segments , 1998, Nature.

[12]  S. Schulz,et al.  Heterodimerization of Substance P and μ-Opioid Receptors Regulates Receptor Trafficking and Resensitization* , 2003, Journal of Biological Chemistry.

[13]  Lakshmi A. Devi,et al.  G-protein-coupled receptor heterodimerization modulates receptor function , 1999, Nature.

[14]  F. Giorgi,et al.  Paired Activation of Two Components within Muscarinic M3 Receptor Dimers Is Required for Recruitment of β-Arrestin-1 to the Plasma Membrane* , 2005, Journal of Biological Chemistry.

[15]  B. O'dowd,et al.  Dopamine D1 and D2 Receptor Co-activation Generates a Novel Phospholipase C-mediated Calcium Signal* , 2004, Journal of Biological Chemistry.

[16]  R. Lefkowitz,et al.  β-Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3 , 2000 .

[17]  R. Lefkowitz,et al.  The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.

[18]  Luigi F Agnati,et al.  Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons , 2003, Pharmacological Reviews.

[19]  S. Allouche,et al.  Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE. , 1999, The Biochemical journal.

[20]  Krzysztof Palczewski,et al.  Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.

[21]  J. W. Wells,et al.  Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. , 2002, Biochemistry.

[22]  H. Lother,et al.  AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration , 2000, Nature.

[23]  E. Lakatta,et al.  Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. , 2002, The Journal of biological chemistry.

[24]  L. Miller,et al.  Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth* , 2003, Journal of Biological Chemistry.

[25]  P. Sigler,et al.  A Model for Arrestin’s Regulation: The 2.8 Å Crystal Structure of Visual Arrestin , 1999, Cell.

[26]  R. Mullins,et al.  β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.

[27]  Ramesh C. Patel,et al.  The Role of Subtype-specific Ligand Binding and the C-tail Domain in Dimer Formation of Human Somatostatin Receptors* , 2004, Journal of Biological Chemistry.

[28]  Pierre Corvol,et al.  Polar Residues in the Transmembrane Domains of the Type 1 Angiotensin II Receptor Are Required for Binding and Coupling , 1996, The Journal of Biological Chemistry.

[29]  E I Canela,et al.  Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Sigler,et al.  Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation. , 2001, Structure.

[31]  M. Bouvier,et al.  Hetero-oligomerization between β2- and β3-Adrenergic Receptors Generates a β-Adrenergic Signaling Unit with Distinct Functional Properties* , 2004, Journal of Biological Chemistry.

[32]  K. Blumer,et al.  Subunits of a Yeast Oligomeric G Protein-coupled Receptor Are Activated Independently by Agonist but Function in Concert to Activate G Protein Heterotrimers* , 2004, Journal of Biological Chemistry.

[33]  Joseph Parello,et al.  Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. , 2003, Journal of molecular biology.

[34]  J. Taylor,et al.  Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  Michel Bouvier,et al.  Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  David J. Daniels,et al.  A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .

[37]  Michel Bouvier,et al.  A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation* , 1996, The Journal of Biological Chemistry.

[38]  J. Banères,et al.  Cooperative Conformational Changes in a G-protein-coupled Receptor Dimer, the Leukotriene B4 Receptor BLT1* , 2004, Journal of Biological Chemistry.

[39]  J. Wess,et al.  Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Mouillac,et al.  Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. , 2003, Molecular endocrinology.

[41]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[42]  L. Devi,et al.  Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Lefkowitz,et al.  β-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor Stimulation* , 2002, The Journal of Biological Chemistry.

[44]  Michel Bouvier,et al.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.

[45]  U. Kumar,et al.  Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.

[46]  Graeme Milligan,et al.  Domain Swapping in the Human Histamine H1 Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[47]  N. Bunnett,et al.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. O'dowd,et al.  Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.

[49]  P. Seeman,et al.  Blockade of G Protein-Coupled Receptors and the Dopamine Transporter by a Transmembrane Domain Peptide: Novel Strategy for Functional Inhibition of Membrane Proteins in Vivo , 2003, Journal of Pharmacology and Experimental Therapeutics.

[50]  E. Lakatta,et al.  β1/β2-Adrenergic Receptor Heterodimerization Regulates β2-Adrenergic Receptor Internalization and ERK Signaling Efficacy* , 2002, The Journal of Biological Chemistry.